West-Ward Recalls Dexamethasone Sodium Phosphate Injection Due to Impurity
West-Ward Pharmaceuticals is recalling Dexamethasone Sodium Phosphate Injection due to high levels of a related compound impurity.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
West-Ward Pharmaceuticals Corp. is recalling 1,896 shelf packs of Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01). The affected product is Lot #106352 with an expiration date of 10/18. The recall was initiated because the product failed impurities/degradation specifications, specifically showing high out-of-specification results for a Dexamethasone adduct, which is a related compound.
The recalled product was distributed nationwide in the USA and Puerto Rico. It is a prescription-only medication administered via intramuscular or intravenous routes. The agency has classified this recall as Class III, indicating that use of or exposure to the product is not likely to cause adverse health consequences.
Healthcare providers and patients should discontinue use of the affected lot and return the product to the distributor or manufacturer for credit. Consumers should check their medication vials for the specific lot number and expiration date listed above.
The recalled product
- Product
- DEXAMETHASONE SODIUM PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE)
- Brand
- DEXAMETHASONE SODIUM PHOSPHATE
- Manufacturer
- West-Ward Pharmaceuticals Corp.
- Category
- Drug — Injection
- Hazard
- Affected units
- 1,896
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 106352
- Exp 10/18
Distribution
Part of a larger recall action
This product is one of 2 recalled by West-Ward Pharmaceuticals Corp. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DEXAMETHASONE SODIUM PHOSPHATE
- HighDexamethasone injection failed impurity specifications at product expiry testing
FDA (Drugs) · 2026-03-25
- HighFDA Recalls Dexamethasone Sodium Phosphate Injection Due to Impurity Specification Failure
FDA (Drugs) · 2024-06-26
- LowWest-Ward Recalls Dexamethasone Sodium Phosphate Injection Due to Impurities
FDA (Drugs) · 2017-11-29
Same manufacturer · West-Ward Pharmaceuticals Corp.
See all →- LowWest-Ward Recalls Sodium Ferric Gluconate Injection Due to Low Iron Content
FDA (Drugs) · 2016-12-14
- LowWest-Ward Recalls Amoxicillin Suspension Due to Missing Strength Label Panel
FDA (Drugs) · 2016-11-30
- ModerateWest-Ward Recalls Phenobarbital Tablets Due to Dissolution Failure
FDA (Drugs) · 2016-11-30
- LowWest-Ward Recalls Amoxicillin Oral Suspension Due to Labeling Error
FDA (Drugs) · 2016-09-28
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17